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Abstract
Background: α-Synuclein is a Parkinson's-disease-related protein. It forms aggregates in vivo, and
these aggregates cause cell cytotoxicity. Aggregation inhibitors are expected to reduce α-synuclein
cytotoxicity, and an aggregation accelerator has recently been reported to reduce α-synuclein
cytotoxicity. Therefore, amyloid aggregation modulating ligands are expected to serve as
therapeutic medicines.
Results: We screened peptide ligands against α-synuclein by in silico panning, a method which we
have proposed previously. In this study, we selected as the target a very hydrophobic region known
as the amyloid-core-forming region. Since this region cannot be dissolved in water, it is difficult to
carry out the in vitro screening of its peptide ligand. We carried out 6 rounds of in silico panning
using a genetic algorithm and a docking simulation. After the in silico panning, we evaluated the top
peptides screened in silico by in vitro assay. These peptides were capable of binding to α-synuclein.
Conclusion: We demonstrated that it is possible to screen α-synuclein-binding peptides by in silico
panning. The screened peptides bind to α-synuclein, thus affecting the aggregation of α-synuclein.
Background
Protein misfolding and aggregation are involved in many
diseases, such as Alzheimer's disease, Parkinson's disease
and Prion disease, and such proteins accumulate as inclu-
sion bodies in the brain. Lewy bodies are inclusion bodies
observed in Parkinson's-disease patients. The major com-
ponent of the Lewy body is amyloid-like fibrils of α-synu-
clein [1]. The familial mutants of α-synuclein A53T, A30P
and E46K accelerate α-synuclein aggregation and/or fibril-
lation and cause autosomal-dominant Parkinson's disease
[2-4]. These results strongly support the idea that α-synu-
clein is the pathogenic protein of Parkinson's disease. It is
known that α-synuclein is one of the natively unfolded
proteins which have little or no ordered secondary struc-
ture under physiological condition. However, changes in
various environmental factors (e.g., pH, ion strength, agi-
tation) induce the formation of α-synuclein aggregates
and amyloid-like fibrils in vitro [5]. Especially, the aggre-
gates called "protofibrils," an intermediate in the fibrillo-
genesis process, have more cytotoxicity than the amyloid-
like fibrils of most of the proteins which generate fibrils
[6]. Therefore, aggregation inhibitors are expected to serve
as therapeutic medicines, and their effect against several
amyloid-forming proteins has been reported [7-11]. How-
ever, inhibitors which do not inhibit protofibril forma-
tion but amyloid fibril formation, such as L-DOPA,
enhance cytotoxicity [12]. Recently, Bodner et al. have
reported that aggregation accelerator compounds decrease
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α-synuclein cytotoxicity [13]. Thus, aggregation accelera-
tors are also expected to serve as therapeutic medicines.
To obtain an effective peptidic aggregation inhibitor, the
peptide should bind to the region that plays an important
role in amyloid fibril formation. The hydrophobic central
region of α-synuclein called the "non-amyloid-β compo-
nent of the amyloid plaque" (NAC) (residues 61–95) is
the most important region in the formation of amyloid-
like fibrils. In particular, some of the partial peptides in
NAC, such as α-synuclein 68–78 (GAVVTGVTAVA), form
amyloid-like fibrils by themselves [14]. We have also
reported that a double mutant (V70T and V71T) of α-
synuclein does not exhibit aggregation and fibrillation
activity. Thus, the binding of peptide ligands to this region
should affect α-synuclein aggregation. However, these
amyloid-core-forming regions are so hydrophobic that
these peptides cannot be dissolved in water. Therefore,
computational screening would be useful to screen lig-
ands against such a target.
Since N-mer peptides have a huge sequence variety (20n),
it is not sufficient to screen the huge sequence space ran-
domly to obtain target peptides. In a previous study, we
have reported an evolutional screening method using
genetic algorithms (GAs) [15-18]. GAs are types of sto-
chastic search algorithms that mimic Darwinian evolu-
tion. GAs can reduce the number of candidates which
should be evaluated, and they have been effectively
applied to screenings of binding poses for docking simu-
lations [19] and the optimization of lead compounds
[20,21]; these studies make reference to our reports. In
such screenings, the peptide sequence can be optimized
by evaluating the biological or chemical activity. Previ-
ously, we have proposed a peptide screening method
using GAs combined with docking simulations: in silico
panning [22]. The scheme of in silico panning is shown in
Figure 1. The first step is the random design of the initial
generation. The second step is the calculation of the dock-
ing energy between the target and the peptides, and the
selection of the superior peptides. The third step is the
crossover of the superior peptide sequences and the intro-
duction of mutations into these sequences; the mutated
sequences are then used for the next round and the oper-
ation is repeated. We have already succeeded in obtaining
peptide inhibitors for glucose dehydrogenase using this
method [22].
In related studies, ADAPT and ENPDA have been reported
[23,24]. ADAPT is a program for designing small mole-
cules, and ENPDA is a program for designing peptide lig-
ands that is similar in methodology to our work; both
methods were effective in screening ligands. In this study,
we carried out in silico panning in order to screen the pep-
tides which bind to the α-synuclein's amyloidogenic
region and affect α-synuclein fibril formation.
Results
In silico panning
We selected an 11-mer peptide, α-synuclein 68–78 (GAV-
VTGVTAVA), as the target region. Although the three-
dimensional structure of α-synuclein has been reported
(1XQ8 [25]), this structure is in the Sodium Dodecyl Sul-
fate (SDS) micelle binding state and its major secondary
structure is an α-helix. Under physiological condition, α-
synuclein does not form a defined structure. Therefore,
Scheme of in silico panning Figure 1
Scheme of in silico panning. In silico panning consists of two steps: a docking simulation and a genetic algorithm. The genetic 
algorithm consists of selection, crossover and point mutation. This figure shows one example of a genetic algorithm.BMC Bioinformatics 2007, 8:451 http://www.biomedcentral.com/1471-2105/8/451
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the unfolded state of the target 11-mer peptide is better
suited as a docking target. Of course, docking simulations
against unfolded proteins are challenging. However, amy-
loid fibrils generally have many β-sheet structures. Since
the target region can aggregate by itself and mutants in
this region lose their aggregation activity, this region is
considered to form β-strands easily. In this study, we
hypothesized that it would show a linear motif. We con-
structed the structure of the target 11-mer peptide using
the MOE protein builder.
Since we have succeeded in screening peptide ligands by
using a tetramer peptide in the previous study, we selected
a tetramer peptide in this study as well. To carry out effec-
tive screening using a genetic algorithm, we restricted the
type of amino acids composing the peptides. In this study,
since the target region was very hydrophobic, we selected
the hydrophobic amino acids and the polar amino acids
that tended to form hydrogen bonds (glycine, alanine,
valine, serine, threonine, proline, glutamine, asparagine,
phenylalanine and tyrosine), and the total diversity is 104
= 10,000. However, even a docking simulation of all
10,000 sequences would be difficult because a peptide
docking simulation requires more time than the docking
simulation of a small compound. We therefore applied a
genetic algorithm to the peptide in silico screening.
First, we evaluated the peptides by their docking energy:
the sum of the intermolecular energy, the intramolecular
energy of the ligand and the desolvation energy. Although
the intramolecular energy is not related to the binding
affinity, we included this energy to eliminate unstable lig-
ands. From the 1st to the 3rd round, the docking energy
decreased through in silico panning (Figure 2(a)). As
expected, a progressive improvement of the docking
energy was observed as the peptides evolved. However,
since the intramolecular energy of some of the superior
peptides was lower than their intermolecular energy, we
removed the intramolecular energy of the ligands from
the evaluation of the docking energy in the next round.
We carried out a total 6 rounds. The results from the 4th to
the 6th generation are shown Figure 2(b). The best peptide
was obtained in the 6th generation. Table 1 shows the pep-
tide ranking after the 6th generation. The peptides were
ranked by their intermolecular energy. The top peptides
had many glutamine residues that can form hydrogen
bonds. Some peptides had a few hydrophobic residues, as
calculated by Generalized Born/Surface Area in a continu-
ous solvent model.
Binding analysis by surface plasmon resonance
The affinities of the screened peptides were determined by
surface plasmon resonance measurement. The screened
peptides were immobilized on a CM5 sensor chip by
amine coupling. In this study, we evaluated QSTQ,
GSQQ, SQTQ and AQTQ which were the top peptides,
and PTYF, which was an inferior peptide. The N-terminal
glutamine could have formed pyroglutamine, and the N-
terminal proline did not have a primary amine. Thus, we
added an alanine residue to the N-terminals of these pep-
tides to immobilize them on the CM5 sensor chip and
evaluated them. The dissociation constants were deter-
mined using a Scatchard plot. We were able to confirm the
peptide binding to α-synuclein, and the KD value of
QSTQ was determined to be 19 μM. AQTQ also bound to
α-synuclein with similar affinity of QSTQ. GSQQ and
SQTQ have lower affinity than QSTQ and AQTQ. In the
Distribution of the docking energy Figure 2
Distribution of the docking energy. The ranks of the 
peptide ligands in each generation are shown on the X- and 
Y-axes. The Z-axis shows the docking energies, which were 
calculated as follows: (a) docking total energy = electrostatic 
energies + van der Waals energies + conformational energy 
of the ligand; (b) interaction energy = total docking energy - 
conformational energy of the ligand. At the 1st to the 3rd gen-
eration, the peptides were evaluated by the total docking 
energy (a); at the 4th to the 6th generation, the peptides were 
evaluated by the interaction energy (b).BMC Bioinformatics 2007, 8:451 http://www.biomedcentral.com/1471-2105/8/451
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case of PTYF, its KD was more than 10 times that of QSTQ.
Since docking simulation still has problems inaccuracy,
we have to evaluate several peptides to find good ligands.
In this study, we can obtain the high affinity peptide by
assaying the top 4 peptides.
Effect of synthetic peptide ligands on α-synuclein 
aggregation
To determine the effect of peptides on α-synuclein aggre-
gation, we co-incubated α-synuclein with 5-fold molar
excess of the screened peptides. The α-synuclein fibril
amounts were evaluated by Thioflavin T (TfT) binding
assay. It is known that when TfT binds to amyloid fibrils,
the fluorescence intensity around 480 nm increases. The
α-synuclein solution without peptide showed an increase
in the fluorescence intensity of TfT after 40 h of shaking
(Figure 3). On the other hand, the α-synuclein solutions
with each top-ranking peptide showed a greater increase
in the fluorescence intensities of TfT than that of the solu-
tion without peptide. Especially, the α-synuclein solution
with the top peptide, QSTQ, showed a fluorescence inten-
sity which was more than 1.5 times stronger than that of
the solution without peptide. Next, to determine whether
or not these increases in fluorescence intensity depend on
the fibril amount, we examined the aggregation amount
by a light scattering assay at 330 nm. The value of optical
density at 330 nm of the α-synuclein solution with the top
peptides was also higher compared with that of the α-
synuclein solution without peptide, as shown in Figure 4.
Especially QSTQ and AQTQ that have similar affinity
showed optical density at 330 nm which was more than
1.5 times stronger than that of the solution with out pep-
tide. The screened peptides showed the promotion of α-
synuclein fibrillation.
Discussion
Peptide docking simulation takes more time than the
docking simulation of small molecules because of the
structural flexibility of peptides. Therefore, it is difficult to
evaluate the peptide library comprehensively by means of
a docking simulation. Yoshimori et al. have proposed a
stochastic approach to reduce the number of evaluated
peptides [26]. Alternatively, we applied a GA to reduce the
number of evaluated peptides. We call this method "in sil-
ico panning," and have previously reported the screening
of a glucose dehydrogenase noncompetitive inhibitor. For
the recognition of the target protein, peptides need to
have functional amino acids, and the amino-acid
sequence is more important than the position of each
amino acid. In some cases, the combination of independ-
ent important amino acids results in loss of binding affin-
Light scattering assay Figure 4
Light scattering assay. The Y-axis shows the normalized 
optical density at 330 nm. 100% is the optical density at 330 
nm of α-synuclein without peptide.
Table 1: Ranking of the superior peptides after in silico panning
Total ranking
Energy(kcal/mol)
No Sequence Total Solvation -ligand
1 QSTQ -390 -260 -233
2 GSQQ -390 -260 -224
3 SQTQ -393 -253 -221
4 AQTQ -342 -251 -217
5 GSQN -383 -243 -217
6 GQQV -408 -255 -211
7 GTTP 115 -237 -211
8 ASTG -329 -237 -210
9 GFNQ -368 -237 -207
10 AGQV -344 -237 -203
Time course of α-synuclein fibril formation Figure 3
Time course of α-synuclein fibril formation. The Y-axis 
shows the normalized fluorescence intensity of Thioflavin T 
at 482 nm. 100% is the final fluorescence intensity of α-synu-
clein without peptide. The samples contained the following: 
α-synuclein (140 μM) without peptide, (Circle); QSTQ, 
(Black diamond); GSQQ, (Empty diamond); SQTQ (Black 
square); AQTQ, (Empty square). All peptide concentrations 
were 700 μM.BMC Bioinformatics 2007, 8:451 http://www.biomedcentral.com/1471-2105/8/451
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ity. The GA can search the sequence space by optimizing
the amino-acid sequence. The GA comprises three steps:
selection, crossover and mutation. Through the operation
of sequence crossover, it is possible to avoid falling into
the local minimum. GAs are used in several fields, espe-
cially in informational science, and the results demon-
strate the efficiency of GA-based screening. In this study,
we evaluated 150 peptides in silico. This represents 1.5%
of the total library, and we succeeded in obtaining the
peptide that affects α-synuclein aggregation and fibrilla-
tion. Therefore, our approach was sufficiently effective for
peptide ligand screening. At present, there are many dock-
ing simulation softwares, and some of them can perform
the calculations more rapidly. Thus, in silico panning has
the potential to be applied it to a larger library.
There are some reports of peptides that affect α-synuclein
aggregation [7,27,28]. These peptides are homologous
peptides. Amyloid-forming proteins, including α-synu-
clein, can form self-aggregates. Therefore, homologous
peptides should bind to the proteins, and these peptides
have the potential to act as protein aggregation inhibitors.
It is known that peptides partially homologous to amy-
loid β bind to amyloid β and the modified homologous
peptide inhibits amyloid β aggregation [9,10]. Concern-
ing α-synuclein, El-Agnaf et al. have reported that peptides
partially homologous in the NAC region, especially the α-
synuclein 60–80 region, bind to α-synuclein across its full
length, and that these peptides, modified to dissolve in
water, inhibit α-synuclein aggregation[7]. Therefore, if the
peptides binding these regions can be screened, they
could be used to inhibit α-synuclein aggregation.
While there are many reports of aggregation inhibitors,
there are some reports of aggregation accelerator peptides
[7,27,28]. These are peptides homologous to the NAC
region. Surprisingly, El-Agnaf et al. have reported that a
peptide designed to inhibit α-synuclein aggregation actu-
ally accelerated the aggregation. This peptide lacks one
amino acid from the α-synuclein aggregation inhibitor
peptide sequence. The protein fibrillation process is
assumed to comprise three steps: conformational change,
the formation of an amyloid core through self-aggrega-
tion, and the elongation of amyloid fibrils. The amyloid-
core-forming region is highly hydrophobic. Thus, this
region should be isolated to some extent from the solvent.
This region may become exposed to the solvent upon the
conformational change resulting from the addition of cer-
tain factors, such as ligands, which might induce the
aggregation of these regions.
The ligand with strong binding activity may inhibit aggre-
gation, which is followed by conformational change.
Since amyloid fibrils have a very stable conformation, it is
thought that the binding ability of self-aggregation is very
strong. Weakly bound ligands would not sufficiently
inhibit this aggregation followed by conformational
change. Therefore, peptides lacking some of the amino
acids of the inhibitor peptide sequence would accelerate
α-synuclein aggregation and induce fibrillation. In this
study, the screened peptides may have bound to the
hydrophobic core region, but the binding ability was not
high. These peptides might induce conformational
changes by binding to the hydrophobic region, and accel-
erate the α-synuclein aggregation and subsequent fibrilla-
tion.
Conclusion
We demonstrated that in silico panning can be used to
screen  α-synuclein-binding peptides. Although α-synu-
clein does not have a defined structure, we were able to
screen the peptides by hypothesizing that the target region
forms a β-sheet structure. The screened peptides showed
low dissociation constants (for example, KD = 19 μM) and
affected  α-synuclein aggregation and fibrillation. These
peptides accelerated α-synuclein aggregation and fibrilla-
tion, and may be able to decrease α-synuclein cytotoxicity
by decreasing the protofibril amount.
Since our in silico panning approach has a great potential
and is applicable to a larger library, it may be useful for the
ligand screening of certain disease-related proteins.
Methods
Construction of the initial generation and target
We designed the peptides of the initial generation ran-
domly, without bias. Since the target peptide, α-synuclein
68–78, is very hydrophobic, we expected that the peptide
ligands would bind to the target peptide through hydro-
phobic interaction and hydrogen bonding. To avoid an
excessively large sequence space, we selected 10 amino
acids: glycine, alanine, valine, serine, threonine, proline,
glutamine, asparagine, phenylalanine and tyrosine. The
molecular operating environment (MOE) from the
Chemical Computing Group, Inc. was used for the model
building. After the three-dimensional construction of
these peptides, in order to optimize these peptides' local
conformations, these structures were subjected to an
MMFF94 energy minimization protocol until the root
mean square of the conjugate gradient reached <0.05 kcal
mol-1 Å-1. The target peptide, α-synuclein 68–78, was con-
structed in the same way.
Docking simulation
The docking simulation described here was carried out
using the MOE-Dock default parameters based on the
simulated annealing protocol. We selected the MMFF94s
force field. The MOE suite utilized here includes an imple-
mented version of the Generalized Born/Surface Area con-
tact function that models the electrostatic contribution toBMC Bioinformatics 2007, 8:451 http://www.biomedcentral.com/1471-2105/8/451
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the free energy of the solvation in a continuous solvent
model. A docking box was constructed around α-synu-
clein 68–78. We carried out the MOE-Dock 30 run in our
case.
Genetic algorithm
We implemented a simple genetic algorithm to produce
the next generation. After the docking simulation, the
peptides were ranked by their calculated docking energy.
The more or less superior peptide sequences were dupli-
cated, and the sequences were recombined at a 1.0 cross-
over rate. Finally, single-amino-acid mutations were
introduced into the peptides at a mutation rate of 5 to
20%. Population sizes of each generation are selected
between 20 and 25 according to number of superior pep-
tide.
Expression and purification of α-synuclein
Human wild-type α-synuclein expressed in Escherichia coli
BL21(DE3) cells transformed the pET28a/human α-synu-
clein WT plasmid. Following induction with 1 mM iso-
propyl-1-thio-β-D-galactopyranoside, the α-synuclein
was purified by anion exchange chromatography [29].
The bacterial cells were harvested by centrifugation at
5,000 g for 10 min and lysed in 500 mM NaCl, 20 mM
Tris-HCl, pH 8.0, and 1 mM EDTA. The lysate was then
boiled for 20 min, and centrifuged for 10 min at 20,000 g.
The supernatant was dialyzed against 20 mM Tris-HCl, pH
8.0, loaded onto a ResourseQ 6-ml column (Amersham
Biosciences) equilibrated in the same buffer, and eluted
with a 0 ~1 M NaCl gradient. The α-synuclein-containing
fraction was dialyzed against 10 mM Tris-HCl, pH 7.4.
Peptide synthesis and purification
All peptides were synthesized using 9-fluorenylmethyoxy-
carbonyl (Fmoc) chemistry and a solid phase system
using the peptide synthesizer PSSM8 (Shimadzu Co., Ltd.,
Kyoto, Japan). The synthesis resin, TentaGel S PHB-cou-
pled Fmoc-amino acid, was purchased from HiPep Labo-
ratories. Deprotection/cleavage from the resin was
performed through treatment with a 90:5:5 (v/v/v) trif-
luoroacetic acid (TFA)/water/triisopropylsilane mixture
for 2 h. Since the glutamine at the N-terminal could
undergo a side-reaction, we conducted the acetylation of
the N-terminal amine. The synthesized peptides were
purified by reverse-phase liquid chromatography using a
C18 ODS-column (TOSOH). The mass weights were con-
firmed by ESI-MS (JEOL).
Surface plasmon resonance
All peptides were immobilized onto the CM5 sensor chip
by amine coupling. The CM5 sensor chip (Biacore) was
activated by an equimolar mix of NHS (N-hydroxysuccin-
imide) and EDC (N-ethyl-N'-(dimethylaminopropyl) car-
bodiimide), coupled with 100 μg/mL of the synthesized
peptide in pH-6.0 sodium acetate buffer, and then
blocked with ethanolamine. For reference, only activation
and protection was carried out, in the same way as men-
tioned above. The final coupling level of each peptide was
approximately 100 RU. Each of the α-synuclein solutions
was injected, and at different concentrations a signal
increase was observed. The sensor surface was regenerated
using 0.5% SDS. The dissociation constants were deter-
mined using a Scatchard plot and an equilibrium point.
Fibril formation and analysis
All the protein samples were concentrated to approxi-
mately 4.0 mg/ml by means of Amicon Ultra-15 filters
(Millipore) in 10 mM Tris-HCl, pH 7.4, and centrifuged at
150,000 g for 60 min to remove the insoluble aggregates.
The peptides were precipitated in the same buffer and
mixed with α-synuclein. The α-synuclein and peptide
mixtures were incubated in 0.5 ml of the same buffer with
0.02% NaN3 at 37°C by shaking in 1.5 ml tubes. The pro-
tein concentrations were kept at approximately 2.0 mg/
ml. Fibril formation was monitored by thioflavin T (TfT)
fluorescence: 10 μl aliquots were sampled from the incu-
bated samples and added to 1.0 ml of 25 μM TfT in 10
mM Tris buffer, pH 7.4. Fluorescence emission was meas-
ured at 485 nm at an excitation wavelength of 450 nm on
a FP6500 spectrofluorometer (JASCO). The Rayleigh scat-
tering at 330 nm was used to monitor the total aggrega-
tion.
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